title: [Effect of integrin-linked kinase on renal tubular epithelial cell transdifferentiation in diabetic rats].
abstract: OBJECTIVE
  To determine the effect of integrin-linked kinase(ILK) in renal tubular epithelial cells and its relation to tubular epithelial-myofibroblast transdifferentiation.
  
  
  METHODS
  Wistar rats were randomly divided into 3 groups, Group normal control (n=10), Group diabetic without therapy(n=10) and Group diabetic with Losartan 20mg/(kg . d)(n=10). Five rats were killed in each group at the 8th and 16th week. The left kidneys were kept for HE and Masson staining to observe the pathological variations in the renal interstitium. ILK, alpha-SMA and Vimentin in renal tubular epithelial cells were detected by immunohistochemistry analysis.
  
  
  RESULTS
  Compared with the control group, ILK, alpha-SMA and Vimentin in renal tubular epithelial cells in Group diabetes gradually increased in immunohistochemistry (P<0.01); ILK was consistent with the pathological variation of renal interstitium and was positively correlated to alpha-SMA(rs=0.621, P<0.05). In comparison with the Group diabetes, the expression of ILK, alpha-SMA and Vimentin in renal tubular epithelial cells was apparently declined (P<0.01) in Group diabetes with Losartan.
  
  
  CONCLUSIONS
  Tubular epithelial myofibroblast transdifferentiation and the over-expression of ILK, between which there may be significant connections, are important events in the progression of diabetic nephropathy. Losartan, a blocker of angiotension II type I receptor, which may down-regulate the expression of ILK in diabetic renal tubular epithelial cells, can restrain the procession of epithelial-myofibroblast transdifferentiation.
authors.affiliation: Department of Nephrology, Xiangya Hospital, Central South University, Changsha 41000, China. ningjp632@yahoo.com.cn
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Ning
authors.forename: Shen
authors.initials: S
authors.lastname: Yang
authors.forename: Chen
authors.initials: C
authors.lastname: Ning
authors.forename: Ying-Hui
authors.initials: YH
authors.lastname: Zeng
authors.forename: Lun-Zhi
authors.initials: LZ
authors.lastname: Liu
authors.forename: Jun
authors.initials: J
authors.lastname: Liu
mesh_terms: D000199:Actins / Q000096:biosynthesis; D000818:Animals; D054338:Cell Transdifferentiation; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000503:physiopathology; D004847:Epithelial Cells / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D005347:Fibroblasts / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D007150:Immunohistochemistry; D007684:Kidney Tubules / Q000473:pathology; D019808:Losartan / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D017346:Protein Serine-Threonine Kinases / Q000096:biosynthesis*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014746:Vimentin / Q000096:biosynthesis; D000099200:Scaffold Protein ILK
chemical_list: D000199:Actins; D019808:Losartan; D017346:Protein Serine-Threonine Kinases; D014746:Vimentin; D000099200:Scaffold Protein ILK